Disease-specific mortality among stage I–III colorectal cancer patients with diabetes: a large population-based analysis by L. V. van de Poll-Franse et al.
ARTICLE
Disease-specific mortality among stage I–III colorectal cancer
patients with diabetes: a large population-based analysis
L. V. van de Poll-Franse & H. R. Haak &
J. W. W. Coebergh & M. L. G. Janssen-Heijnen &
V. E. P. P. Lemmens
Received: 26 October 2011 /Accepted: 14 March 2012 /Published online: 24 April 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract
Aims/hypothesis The aim of our study was to investigate
overall and disease-specific mortality of colorectal cancer
patients with diabetes.
Methods In this population-based study, we included all
colorectal cancer patients, newly diagnosed with stage
I–III cancer, between 1997 and 2007 in the registration area
of the Eindhoven Cancer Registry. Stage of cancer, cancer
treatment and comorbidities were actively collected by
reviewing hospital medical records. Data on patients with
and without diabetes were linked to Statistics Netherlands to
assess vitality, date of death and underlying cause of death.
Follow-up of all patients was completed until 1 January
2009.
Results We included 6,974 patients with colon cancer and
3,888 patients with rectal cancer, of whom 820 (12%) and
404 (10%), respectively, had diabetes at the time of cancer
diagnosis. During follow-up, death occurred in 611 (50%)
of 1,224 cancer patients with diabetes and 3,817 (40%) of
9,638 cancer patients without diabetes. Multivariate Cox
regression analyses, adjusted for age, sex, socioeconomic
status, stage, lymph nodes examined, adjuvant therapy and
year of diagnosis, showed that overall mortality was signif-
icantly higher for colon (HR 1.12, 95% CI 1.01, 1.25) and
rectal (HR 1.21, 95% CI 1.03, 1.41) cancer patients with
diabetes than for those without. Disease-specific mortality
was only significantly increased for rectal cancer patients
(HR 1.30, 95% CI 1.06, 1.60).
Conclusions/interpretation Diabetes at the time of rectal
cancer diagnosis was independently associated with an in-
creased risk of colorectal cancer mortality compared with no
diabetes, suggesting a specific interaction between diabetes
and rectal cancer. Future in-depth studies including detailed
diabetes- and cancer-related variables should elucidate
pathways.
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The number of older people with cancer is increasing con-
siderably, resulting in a growing proportion of patients who
present with multiple coexisting medical conditions [1].
Worldwide, a strongly increasing prevalence of diabetes
has been observed [2–4]. Breast, colorectal, endometrial,
pancreatic and kidney cancer are more prevalent in patients
with diabetes than in those without diabetes. Furthermore,
the prevalence of diabetes in these patients is also higher
than in other cancer patients or patients without cancer [5]. It
is estimated that the number of newly diagnosed cancer
patients with diabetes in the Netherlands will double from
5,500 in 2000 to 10,400 in 2015 [6].
Since 1993, the Eindhoven Cancer Registry (ECR) has
registered the prevalence of comorbid conditions at the time
of cancer diagnosis. About 60% of all newly diagnosed
cancer patients older than 65 years had at least one other
serious disease, of which diabetes was one of the most
common (16%) [1]. In a population-based analysis of all
58,498 cancer patients diagnosed between 1995 and 2002 in
the southern Netherlands, we showed that patients with pre-
existing diabetes had a significantly increased overall mor-
tality [5]. This result was confirmed by a meta-analysis that
included our paper and 22 other papers [7], and a review that
focused on colorectal cancer [8].
In 2010, the American Diabetes Association and
American Cancer Society reviewed the state of science
concerning diabetes and cancer [9, 10]. One of the key
issues was a better understanding of whether diabetes influ-
ences cancer prognosis above and beyond the prognosis
conferred by each disease state independently. Today, only
a few studies have evaluated disease-specific mortality
among cancer patients with diabetes. Poorly controlled,
pre-existing diabetes mellitus has been associated with an
increased risk of death attributable to colorectal cancer [11].
Similarly, hyperinsulinaemia and five other previously
established components of metabolic syndrome were shown
to be prospective risk factors for deaths that can be ascribed
to prostate cancer [12]. Furthermore, an increased risk was
also observed for endometrial cancer mortality among wom-
en with diabetes [13]. Recently, the large prospective Cancer
Prevention Study-II Nutrition Cohort showed increased co-
lorectal cancer mortality among patients with colorectal
cancer and diabetes [14]. However, other studies found no
association between diabetes- and cancer-specific mortality
[15–18]. These conflicting results may be explained by
small numbers of diabetes patients, a limited number of
deaths, and/or no information about cancer treatment
[11–13, 15–18].
The aim of our study was to investigate the overall and
disease-specific mortality of colorectal cancer patients with
diabetes, taking into account differences in age, comorbidity
(especially cardiovascular diseases [CVDs]), stage and treat-
ment according to diabetes status. In view of the variable
associations between diabetes and cancer risk at specific
sites [9, 10, 19], we analysed our data for colon and rectal
cancer separately.
Methods
Patients and methods The ECR records data on all patients
newly diagnosed with cancer in the southern part of the
Netherlands, an area with 2.3 million inhabitants, ten gen-
eral hospitals and two large radiotherapy institutes. Trained
registration clerks actively collect data on diagnosis and
staging (tumour, nodes, metastasis [TNM]) and detailed
information about initial treatment from hospital medical
records. Registration takes place 6–12 months after diagno-
sis. By means of an independent case ascertainment method,
the completeness of the registration has been estimated to
exceed 95% [20]. The medical record is generally regarded
as the most complete source of information on the patient’s
past and current health status [21]. Since 1993, serious
comorbidity with prognostic impact has been recorded for
all patients. A slightly modified version of the widely used
Charlson comorbidity index [22] is used [1]. Comorbidity
was defined as life-shortening diseases that were present at
the time of cancer diagnosis. Drug use, often recorded from
general practitioners’ letters, served as an indicator of active
disease. Diabetes mellitus included both type I and type II
disease and was registered as a dichotomous variable
(yes/no), as were all other concomitant conditions. CVD
included myocardial infarction, cardiac insufficiency,
angina pectoris, coronary artery bypass graft, peripheral
arterial disease, and cerebrovascular diseases. Comorbidity
data since 1995 are considered accurate, i.e. complete and
correct.
We included all colorectal cancer (International Classifi-
cation of Diseases for Oncology codes C18.0–C20.9)
patients, newly diagnosed with stage I–III cancer, between
1997 and 2007. We excluded patients for whom the site of
the primary tumour within the colorectum was not known
(1.5% of total). Oncological treatment was defined as sur-
gery, radiotherapy and/or chemotherapy. Surgery did not
comprise diagnostic operations. Data on patients with colo-
rectal cancer with or without diabetes from the population-
based ECR were linked to mortality data from the database
of Statistics Netherlands.
Statistics Netherlands registers vital status, including, if
applicable, date of death of a person as recorded by the
municipal population registries. Statistics Netherlands also
documents the primary underlying cause of death (UCOD)
as recorded by the attending physician. This is performed
according to the World Health Organization UCOD definition
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‘the disease or injury which initiated the chain of morbid
events leading directly to death, or the circumstances of the
accident or violence which produced the fatal injury’ and in
accordance with the rules of the International Classification
of Diseases-tenth revision. Follow-up of all patients was
completed until 1 January 2009.
Postal codes of residential areas are used to establish the
socioeconomic status (SES) of diagnosed cancer patients,
also provided by Statistics Netherlands [23]. At the six-
position level of postal code, data on household income
and economical value of the house are available from fiscal
data. This information was transformed into four categories:
low, medium and high SES and patients who were institu-
tionalised (such as in a nursing home). ECR and Statistics
Netherlands data were linked by use of postal codes and
dates of birth. If patients could not be found in Statistics
Netherlands with this strategy, date of death was also
provided by the ECR to track the patient in Statistics
Netherlands files.
Statistical analysis The SAS computer package (version 9.1
for Windows; SAS Institute, Cary, NC, USA) was used for
all statistical analyses. All analyses were performed sepa-
rately for colon and rectal cancer patients. Differences in
patient, tumour and treatment characteristics according to
diabetes status were tested by χ2 analysis or t test, as
appropriate. Non-parametric equivalents were applied when
normality and homogeneity assumptions were violated.
Survival analysis was carried out using the life table method
to evaluate the prognosis after diagnosis for cancer patients
with or without diabetes. Survival time was defined as the
time from diagnosis to death or 1 January 2009 for the
patients who were still alive. Five-year cumulative survival
probability and its standard error were calculated for those
with or without diabetes and compared by means of the
logrank test.
The independent prognostic effect of diabetes on overall
mortality and colorectal cancer-specific mortality was esti-
mated using Cox proportional hazards regression models.
The proportional hazard assumption of diabetes was evalu-
ated by estimating Kaplan–Meier curves. The effect of
diabetes over time satisfied the assumption of proportional-
ity as the graphs of the log (log[survival]) versus log of
survival time exhibited parallel lines for the groups of dia-
betic and non-diabetic patients. Confounding variables in-
cluded for adjustment in the Cox proportional hazards
regression models were determined a priori [24]: age at
diagnosis, sex, stage, number of examined lymph nodes
(≥10), adjuvant therapy (chemotherapy or radiotherapy),
SES, year of diagnosis, hypertension, CVD, cerebrovascular
disease, previous cancer and lung disease. Effect modifica-
tion between diabetes and all potential confounding varia-
bles was assessed by adding interaction terms diabetes×
confounding variable in the multivariate Cox proportional
hazards regression models. HRs with 95% CIs and p values
are reported.
Results
Between 1997 and 2007, 15,655 colorectal cancer patients
were diagnosed in the ECR area (Fig. 1). Of these, 15,449
(99%) were successfully linked with Death Statistics
Netherlands. After exclusion of patients with stage IV dis-
ease or missing information on stage, we included 6,974
colon cancer and 3,888 rectal cancer patients with stage I–III
disease, of whom 820 (12%) and 404 (10%), respectively,
had diabetes at cancer diagnosis. Colon cancer patients with
diabetes were on average 4 years older than their counter-
parts without diabetes, had a lower SES, more additional
comorbid conditions and less often received adjuvant sys-
temic therapy (Table 1). Colon cancer patients with diabetes
had more often been diagnosed with a previous cancer,
hypertension, CVD, cerebrovascular accident (CVA) and
lung disease than those without diabetes. There were no
differences in sex, stage, grade and number of lymph nodes
examined. Although not statistically significant, colon can-
cer patients with diabetes appeared to be diagnosed more
often in more recent periods than those without diabetes.
Rectal cancer patients with diabetes were on average 5 years
older than their counterparts without diabetes, and had a lower
SES and more additional comorbid conditions (Table 2).
Rectal cancer patients with diabetes also had been diagnosed
more often with a previous cancer, hypertension, CVD, CVA
and lung disease. There were no differences in the presence of
diabetes with respect to sex, stage, grade, number of examined
lymph nodes, and receipt of adjuvant therapy or period of
diagnosis.
15,655 colorectal cancer patients
diagnosed between 1997 and 2007
15,449 (99%) were successfully linked 







not be linked with
Death Statistics
Netherlands
9,638 (89%) non-diabetes 1,224 (11%) diabetes
10,862 stage I–III disease
3,817 (40%) deceased,
of whom 2,278 (60%) died
because of colorectal cancer
611 (50%) deceased,
of whom 323 (53%) died
because of colorectal cancer
Fig. 1 Flow chart of patient selection
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Of all 10,862 patients diagnosed in the period 1997–
2007, 4,428 (41%) deaths were registered up to the
follow-up date 1 January 2009 (Table 3). Evaluation of
UCOD showed that colon cancer patients most often died
of colon cancer (52% of those without diabetes vs 44% with
diabetes), whereas in 2% of the patients, rectal cancer was
registered as the UCOD. Of the patients diagnosed with
rectal cancer, 23% had colon cancer registered as their
UCOD. As misclassification of cause of death may have
played a role here, we decided to investigate colorectal
Table 1 Characteristics of patients with colon cancer stage I–III






Male 376 (46) 3,119 (51) 0.0094
Age (years) 73.0±8.8 68.8±11.1 <0.0001
Age
0–59 66 (8) 1,218 (20)
60–69 191 (23) 1,707 (28)
70–79 354 (43) 2,201 (36)
80+ 209 (25) 1,028 (17) <0.0001
Stage
I 150 (18) 1,221 (20)
II 409 (50) 2,849 (46)
III 261 (32) 2,084 (34) 0.15
Examined lymph nodes
Median (25–75%) 7 (3–11) 7 (4–11)
≥10 197 (32) 1,544 (33) 0.48
Therapy
Surgery alone 677 (83) 4,715 (77)
Surgery and systemic 118 (14) 1,257 (20)
Other/unknown 25 (3) 182 (3) 0.0008
SES
Low 291 (36) 1,610 (27)
Medium 276 (34) 2,305 (38)
High 174 (22) 1,819 (30)
Institutionalised 68 (8) 296 (5) <0.0001
Comorbidity, excluding diabetes
0 163 (20) 2,098 (34)
1 285 (35) 1,946 (32)
2 or more 372 (45) 1,450 (24)
Missing 0 (−) 660 (11) <0.0001
Type of comorbidity
Previous cancer 135 (16) 822 (13) 0.015
Hypertension 365 (45) 1,242 (20) <0.0001
CVD 344 (42) 1,441 (23) <0.0001
CVA 80 (10) 239 (4) <0.0001
Lung diseases 101 (12) 557 (9) 0.003
Period of cancer diagnosis
1997–1999 176 (21) 1,401 (23)
2000–2002 200 (24) 1,721 (28)
2003–2005 255 (31) 1,746 (28)
2006–2007 189 (23) 1,286 (21) 0.061
Unless otherwise stated, values are n (%) or mean±SD
Table 2 Characteristics of patients with rectal cancer stage I–III






Male 230 (57) 2,081 (57) 0.28
Age (years) 71.2±8.4 66.1±11.2 <0.0001
Age
0–59 42 (10) 964 (28)
60–69 121 (30) 1,119 (32)
70–79 173 (43) 1,004 (29)
80+ 68 (17) 397 (11) <0.0001
Stage
I 133 (33) 1,253 (36)
II 142 (35) 1,156 (33)
III 129 (32) 1,075 (31) 0.47
Examined lymph nodes
Median (25–75%) 5 (2–8) 5 (2–9)
≥10 68 (21) 529 (20) 0.52
Therapy
Surgery alone 152 (38) 1,156 (33)
Surgery + radiotherapy 183 (45) 1,647 (47)
Surgery + radiotherapy + systemic 40 (10) 408 (12)
Surgery + systemic 14 (3) 146 (4)
Other/unknown 15 (3) 127 (4) 0.23
SES
Low 134 (34) 794 (23)
Medium 152 (38) 1,364 (40)
High 88 (22) 1,111 (33)
Institutionalised 26 (7) 139 (4) <0.0001
Comorbidity, excluding diabetes
0 79 (19) 1,436 (41)
1 152 (38) 1,060 (30)
2 or more 173 (43) 634 (18)
Missing 0 (−) 660 (11) <0.0001
Type of comorbidity
Previous cancer 67 (17) 344 (10) <0.0001
Hypertension 195 (48) 669 (19) <0.0001
CVD 154 (38) 650 (19) <0.0001
CVA 34 (8) 105 (3) <0.0001
Lung diseases 46 (11) 294 (8) 0.047
Period of cancer diagnosis
1997–1999 79 (20) 781 (22)
2000–2002 100 (25) 927 (27)
2003–2005 134 (33) 1,065 (31)
2006–2007 91 (23) 711 (20) 0.33
Unless otherwise stated, values are n (%) or mean ± SD
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cancer death as one group in patients diagnosed with colon
or rectal cancer. Therefore, throughout this paper, disease-
specific survival or mortality always includes both colon
and rectal cancer as the primary cause of death or underlying
complication. Cancer patients with diabetes more often had
diabetes registered as UCOD (4%) or diseases of the circu-
latory system (18%) compared with cancer patients without
diabetes (0% and 12%, respectively).
Compared with patients without diabetes, 5-year overall
survival was 9% lower among colon cancer patients and
14% lower among rectal cancer patients with diabetes. The
10-year overall survival rates were 22% and 17% lower,
respectively. Differences in cancer-specific 5- and 10-year
survival were somewhat smaller (2–9%).
Unadjusted analyses revealed that the overall survival of
cancer patients without diabetes was significantly higher
than survival of those with diabetes (Figs 2, 3, 4 and 5).
For colon and rectal cancer, the observed unadjusted HR for
the effect of diabetes on overall mortality was 1.42 (95% CI
1.28, 1.57) and 1.58 (95% CI 1.36, 1.84), respectively.
Multivariate Cox proportional hazards regression analyses,
with adjustment for differences in age, sex, SES, stage,
number of lymph nodes examined, receipt of adjuvant ther-
apy and period of diagnosis, showed that overall mortality
remained significantly higher for colon (HR 1.22, 95% CI
1.09, 1.34) and rectal (HR 1.29, 95% CI 1.11, 1.50) cancer
patients with diabetes (data not shown). Bivariate analyses
showed that age, sex and therapy were the strongest
confounding variables that resulted in a dilution of the effect
of diabetes on overall mortality. Further adjustment for
hypertension, CVD, cerebrovascular disease, previous can-
cer and lung disease lowered the HR for overall mortality
even further in colon (HR 1.12, 95% CI 1.01, 1.25; Table 4)
and rectal (HR 1.21, 95% CI 1.03, 1.41; Table 5) cancer
patients with diabetes. CVD was the strongest additional
confounding factor in this step, although diabetes remained
an independent predictor of overall mortality in colon and
rectal cancer patients.
Table 3 Number and
percentages of patients, deaths,
causes of death and survival
according to cancer subsite and
diabetes status
Values are n (%) or %
CRC, colorectal cancer; NOS,
not otherwise specified
aColon cancer as underlying
cause of death
bRectal cancer as underlying
cause of death
Characteristic Colon Rectal
Diabetes No diabetes Diabetes No diabetes
Number of patients 820 6,154 404 3,484
Number of deaths 417 (51) 2,525 (41) 194 (48) 1,292 (37)
UCOD
CRC 194 (47) 1,376 (55) 110 (57) 759 (59)
Colon cancera 184 (44) 1,313 (52) 45 (23) 301 (23)
Rectal cancerb 10 (2) 63 (2) 65 (34) 458 (35)
NOS digestive cancer 24 (6) 159 (6) 8 (4) 84 (7)
Other cancers 42 (10) 292 (12) 13 (7) 126 (10)
Diabetes 20 (5) 7 (0.3) 5 (3) 3 (0.2)
Circulatory system 75 (18) 332 (13) 36 (19) 138 (11)
Respiratory disease 21 (5) 98 (4) 7 (4) 58 (4)
External causes 4 (1) 26 (1) 1 (0.5) 16 (1)
Infections 3 (0.7) 23 (1) 1 (0.5) 17 (1)
Other 34 (8) 212 (8) 13 (7) 91 (7)
Survival
5-year overall 51 60 50 64
10-year overall 22 22 31 48
5-year CRC-specific 73 75 67 75




















Fig. 2 Overall survival for stage I–III colon cancer patients with (solid
line) or without (dashed line) diabetes
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Cancer-specific mortality was also increased among co-
lorectal cancer patients with diabetes. Unadjusted analyses
showed a small increased risk of cancer-specific mortality in
colon cancer patients with diabetes compared with those
without diabetes (HR 1.17, 95% CI 1.01, 1.36; data not
shown). However, after adjustment for confounding varia-
bles, this increased risk disappeared (HR 1.05, 95% CI 0.90,
1.23; Table 4). Bivariate analyses showed that age, sex and
receipt of adjuvant therapy were the strongest confounding
variables, whereas addition of having had a previous cancer
or other comorbidities to the multivariate model did not
significantly change the observed HR. We also observed a
statistically significant interaction between diabetes and sex
for patients with colon cancer. Women with colon cancer
and diabetes had an increased risk of colon cancer mortality,
whereas men did not. However, after adjustment for age,
this finding disappeared.
Cancer-specific mortality was significantly increased
among rectal cancer patients with diabetes compared with
those without (HR 1.48; 95% CI 1.21, 1.81; data not




















Fig. 3 Colorectal cancer-specific survival for stage I–III colon cancer




















Fig. 4 Overall survival for stage I–III rectal cancer patients with (solid




















Fig. 5 Colorectal cancer-specific survival for stage I–III rectal cancer
patients with (solid line) or without (dashed line) diabetes
Table 4 Multivariate Cox regression analyses of the effect of diabetes
on overall and colorectal cancer-specific mortality in stage I–III colon
cancer
Characteristic Overall mortality Colorectal cancer
mortality
Diabetes (vs no) 1.12 (1.01, 1.25)* 1.05 (0.90, 1.23)
Male sex (vs female sex) 1.22 (1.13, 1.31)** 1.12 (1.01, 1.24)*
Age (per 1 year increase) 1.04 (1.04, 1.05)** 1.02 (1.01, 1.03)**
Period of cancer diagnosis
1997–1999 1 1
2000–2002 0.99 (0.89, 1.10) 0.89 (0.77, 1.03)
2003–2005 0.93 (0.82, 1.04) 0.91 (0.77, 1.06)
2006–2007 0.80 (0.68, 0.94)** 0.86 (0.70, 1.06)
Stage
I 1 1
II 1.64 (1.46, 1.83)** 2.60 (2.14, 3.17)**
III 3.17 (2.80, 3.60)** 6.83 (5.56, 8.39)**
Examined lymph nodes ≥10
(vs no)
0.69 (0.62, 0.77)** 0.62 (0.53, 0.71)**
Systemic therapy (vs no) 0.68 (0.61, 0.77)** 0.69 (0.59, 0.80)**
SES
Low 1 1
Medium 0.94 (0.86, 1.03) 0.98 (0.87, 1.11)
High 0.87 (0.79, 0.96)** 0.91 (0.70, 1.05)
Institutionalised 1.09 (0.94, 1.27) 0.96 (0.77, 1.20)
Hypertension (vs no) 0.97 (0.89, 1.06) 0.89 (0.79, 1.01)
CVD (vs no) 1.33 (1.23, 1.45)** 1.12 (0.99, 1.26)
CVA (vs no) 1.32 (1.14, 1.53)** 1.21 (0.97, 1.50)
Previous cancer (vs no) 1.32 (1.20, 1.46)** 1.26 (1.10, 1.45)**
Lung disease (vs no) 1.16 (1.04, 1.30)** 1.09 (0.93, 1.29)
Values are HR (95% CI)
*p<0.05
**p<0.01
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significantly higher for rectal cancer patients with diabetes
than for those without diabetes (HR 1.30, 95% CI 1.06,
1.41; Table 5). Again, age and sex appeared to be strong
confounding variables, changing the HR by more than 10%,
whereas addition of having had a previous cancer or other
comorbidities to the multivariate model did not significantly
change the observed HR. There was no interaction between
diabetes and age, stage, number of lymph nodes examined,
receipt of adjuvant therapy, SES and year of diagnosis on
(disease-specific) mortality among colon or rectal cancer
patients.
Discussion
This population-based study on more than 10,000 stage I–III
colorectal cancer patients reveals that diabetes at the time of
rectal cancer diagnosis was associated with an HR of 1.30
for the risk of colorectal cancer mortality compared with
those without diabetes. Colon cancer patients with diabetes
did not have an increased risk of death from colorectal
cancer compared with those without. Furthermore, our
results confirm previous findings that overall mortality was
increased among patients with pre-existing diabetes at colon
or rectal cancer diagnosis.
A previous meta-analysis showed that patients diagnosed
with cancer who had pre-existing diabetes were at increased
risk of long-term, all-cause mortality compared with those
without diabetes [7]. It is, however, possible that the excess
mortality risk related to diabetes is completely independent
of cancer and cancer treatment. In order to understand
whether diabetes influences cancer prognosis above and
beyond the prognosis by each disease state independently,
one should evaluate disease-specific mortality and adjust for
potential differences in cancer stage or treatment between
patients with and without diabetes. However, the subsidiary
meta-analysis of studies that distinguished between cancer
and non-cancer mortality was inconclusive [7], as only a
few studies have evaluated disease-specific mortality
among cancer patients with diabetes. These studies yielded
conflicting results because of a small number of diabetes
patients, a limited number of deaths, or no information
about cancer treatment [12, 13, 15–18]. Nevertheless, recent
analyses of a large prospective cohort showed increased all-
cause mortality, colorectal cancer-specific mortality and
CVD-specific mortality among colorectal cancer patients
with diabetes [14].
In our study we again observed that colon cancer patients
with diabetes less often received adjuvant chemotherapy
than non-diabetic cancer patients [5, 25]. This apparently
also confounded the association between diabetes and can-
cer mortality among colon cancer patients. This observation
is confirmed in a systematic review that evaluated 34 studies
on the impact of comorbidity on chemotherapy use and
outcomes [26]. Most studies in this review reported lower
use of chemotherapy and worse outcomes among cancer
patients with comorbidities [27, 28].
For rectal cancer, we did not observe a different stage
distribution or less aggressive treatment in patients with
concurrent diabetes. Therefore our current findings may
imply that the increased disease-specific mortality risk in
rectal cancer patients with diabetes follows from a specific
interaction between diabetes and cancer.
Several explanations for a worse disease-specific out-
come have been discussed in previous papers. It is possible
that diabetic patients respond differently to adjuvant thera-
pies. A small retrospective review in rectal cancer patients
showed that diabetic patients (n017) showed higher local
progression rates after neoadjuvant chemoradiotherapy than
non-diabetic patients (n093), whereas none of the diabetic
Table 5 Multivariate Cox regression analyses of the effect of diabetes
on overall and colorectal cancer-specific mortality in stage I–III rectal
cancer
Characteristic Overall mortality Colorectal cancer
mortality
Diabetes (vs no) 1.21 (1.03, 1.41)* 1.30 (1.06, 1.60)*
Male sex (vs female sex) 1.16 (1.04, 1.29)** 1.14 (0.99, 1.31)
Age (per 1 year increase) 1.05 (1.04, 1.05)** 1.03 (1.03, 1.04)**
Period of cancer diagnosis
1997–1999 1 1
2000–2002 1.11 (0.96, 1.29) 0.92 (0.76, 1.11)
2003–2005 0.82 (0.69, 0.97)* 0.66 (0.53, 0.82)**
2006–2007 0.76 (0.61, 0.97)* 0.60 (0.45, 0.81)**
Stage
I 1 1
II 1.80 (1.58, 2.06)** 3.03 (2.46, 3.73)**
III 2.66 (2.33, 3.05)** 5.02 (4.07, 6.18)**
Examined lymph nodes ≥10
(vs no)
0.84 (0.71, 1.00)* 0.79 (0.63, 0.98)*
Radiotherapy (vs no) 0.98 (0.88, 1.09) 1.06 (0.92, 1.23)**
SES
Low 1 1
Medium 0.78 (0.68, 0.88)** 0.77 (0.65, 0.91)**
High 0.75 (0.66, 0.86)** 0.84 (0.70, 1.00)*
Institutionalised 1.35 (1.09, 1.68)** 1.32 (0.98, 1.78)
Hypertension (vs no) 1.12 (1.00, 1.27) 1.00 (0.85, 1.20)
CVD (vs no) 1.23 (1.09, 1.40)** 1.00 (0.84, 1.20)
CVA (vs no) 1.05 (0.81, 1.34)** 0.95 (0.66, 1.36)
Previous cancer (vs no) 1.19 (1.02, 1.38)* 1.00 (0.80, 1.25)
Lung disease (vs no) 1.41 (1.20, 1.66)** 1.37 (1.10, 1.71)*
Values are HR (95% CI)
*p<0.05
**p<0.01
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patients achieved a pathological complete response [29].
Also, Meyerhardt and colleagues found a significantly
higher rate of cancer recurrence and overall mortality
among diabetic cancer patients in an adjuvant chemother-
apy trial for colon cancer patients, suggesting a smaller
effect of therapy [30]. In a review on colorectal cancer
outcomes in patients with and without diabetes, an in-
creased risk of cancer recurrence, non-response to chemo-
radiotherapy and treatment-related complications was
reported [8]. However, the authors’ overall conclusion
was that much of the long-term mortality risk in colorectal
cancer patients with diabetes can be attributed to causes
other than cancer.
In our study, we did not observe a significant interaction
effect between adjuvant chemotherapy or radiotherapy and
diabetes on survival. Unfortunately, as in most studies in
this field [26], we did not have information about tolerabil-
ity or toxicity of treatment in diabetes patients.
Another explanation for the increased mortality risk is
increased tumour cell proliferation and metastases in a
physiological environment of hyperinsulinaemia and
hyperglycaemia, leading to a worse prognosis [31]. Studies
among non-diabetic breast and colon cancer patients
revealed that high levels of fasting insulin had an adverse
prognostic effect on distant recurrence and death [32, 33].
In addition, retrospective, observational studies on diabetic
treatment suggest that long-acting insulin glargine (A21Gly,
B31Arg,B32Arg human insulin) may increase the risk of
cancer [34], whereas biguanide metformin may decrease
cancer risk [35, 36] and cancer mortality [37]. Furthermore,
obesity and physical inactivity are also associated with
disease progression and mortality in non-diabetic colorectal
cancer patients [38–43]. The mediators for the elevated risk
of colorectal cancer, cancer recurrence and death are not
known, but are thought to be related to hyperinsulinaemia,
insulin resistance, insulin-like growth factor, adipocytokines
and inflammatory cytokines [44, 45]. All these findings
suggest that hyperinsulinaemia may stimulate cancer pro-
gression, due to its mitogenic effect [46], and support the
idea of biological interaction. However, the clinical rele-
vance of the pro-cancer effect of insulin in diabetic patients
is still unclear [46].
As we unfortunately did not have information about the
diabetes duration and insulin requirement, as well as meta-
bolic control and body mass index, we hope that our
planned studies in this field will answer these questions.
Another limitation of this study is the fact that we did not
have information about the number of chemotherapy or
radiotherapy courses and possible interruption of treatment
due to complications in those with or without diabetes.
Furthermore, although we believe that a large population-
based study that combines cancer stage and treatment vari-
ables with cause-specific mortality data is very much needed
in this field, the latter also has limitations. Attribution of
cause of death is often problematic, especially for colorectal
cancer, where records for the UCOD do not accurately
specify between colon and rectal cancers [47]. We observed
that 2% of patients diagnosed with colon cancer had rectal
cancer as the UCOD, whereas 34% of rectal cancer patients
had colon cancer as the UCOD. These findings are compa-
rable to a recent US study in which the UCOD records
disagreed with California Cancer Registry records for 700
(6%) of 11,404 colon cancer deaths and with 1,958 (39%) of
5,011 rectal cancer deaths, and 82% of the misclassified
rectal cancer deaths were coded as colon cancer deaths in
the UCOD [47]. Reclassification decreased cause-specific
survival for both colon and rectal cancers, but the impact
was more pronounced for rectal cancer. Interchangeable use
of the terms colon cancer and colorectal cancer is probably
one of the reasons for UCOD misclassification. Neverthe-
less, we believe that by including colon and rectal cancer as
the cause of death for both sites, we did not overestimate
cause-specific survival. Also, this apparent misclassification
is unlikely to have been systematically different for patients
with or without diabetes.
Another limitation is the fact that we analysed colorec-
tal cancer death in the presence of competing risks, such
as death due to cardiovascular events. As diabetic cancer
patients have a higher risk of dying from a cardiovascular
event than cancer patients without diabetes, Kaplan–Meier
estimates as well as standard Cox regression may have
overestimated the actual incidence of cancer death [48].
Therefore it is important not to ignore other causes of
death and also include overall mortality analyses to obtain
a comprehensive picture of the impact of diabetes on
outcomes.
Furthermore, we were not able to include mortality in-
formation from the background population without cancer.
While most studies among non-cancer populations find
standardised mortality ratios of 2–3 for diabetes vs non-
diabetes in a similar age-group [49, 50], this study
finds much lower HRs for comparisons of diabetes with
non-diabetes.
In conclusion, this large population-based study has
confirmed previous findings that overall mortality is in-
creased among patients with pre-existing diabetes at diag-
nosis of colon or rectal cancer. Most interesting was our
observation that diabetes at the time of rectal cancer
diagnosis was associated with an increased risk of colo-
rectal cancer mortality compared with no diabetes. As this
was not explained by differences in stage or treatment of
rectal cancer patients with or without diabetes, there might
be a specific interaction between diabetes and rectal
cancer. We aim to elucidate pathways in future in-depth
studies including detailed diabetes- and cancer-related
variables.
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